US Stock Market Movement: Twist Bioscience Plummets on October 12 Due to High Valuation, Institutional Sell-Off, and Interest Rate Pressure

Twist Bioscience Plummets on October 12: Analysis

Keywords: Overvaluation, Institutional Selling, Interest Rate Pressure

1. On October 13, 2026, Federal Reserve officials stated that interest rates need to be higher, increasing discount rate pressure on high-valuation growth stocks.

2. On October 8, 2026, analysis indicated that the company's stock price rise has outpaced its fundamentals and the commercialization progress of AI drug development, leading to an overvaluation; year-to-date, the company's cumulative increase remains at 367.21%, creating significant profit-taking pressure.

3. On October 6, 2026, ARK Invest's fund sold approximately 90,700 shares of TWST, amounting to about $18 million; during the same period, the genomics sector weakened, with NeoGenomics and 10x Genomics declining, increasing the selling pressure on the sector and individual stocks.

(Disclaimer: This content is collected and summarized by AI technology from publicly available information and is for reference only. It does not constitute investment advice.)